All In Biotech

Drug Trial Radar · NCT00750139

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis

A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis

Last checked: Nov 20, 2026Latest source record: Apr 26, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 707 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

707

Actual

Start

Aug 2008

Primary completion

Aug 2009

Study completion Dec 2009

Sponsor

Lead sponsor
Merz North America, Inc.Industry
Sponsor type
Industry
First posted
Sep 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo, when used in subjects with tinea pedis (athlete's foot).

Conditions

  • Tinea Pedis
  • Athlete's Foot

Interventions

  • NAFT-500Drug

    topical cream 1 application every day up to 4 weeks weeks

  • Placebo 2-weeksDrug

    placebo cream 1 application every day for up to 4 weeks

  • Naftin 1%Drug

    topical allylamine cream applied once a day for up to 4 weeks

  • Placebo 4-weeksDrug

    topical placebo cream applied once a day for up to 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Complete Cure at Week 6.Time frame: Week 6

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Radiant Research

    Birmingham, Alabama

  • Dr. Felix Sigal

    Los Angeles, California

  • University of California San Francisco, Dept of Dermatology

    San Francisco, California

  • FXM Research

    Miami, Florida

  • FXM Research

    Miramar, Florida

  • Glazer Dermatology

    Buffalo Grove, Illinois

  • Tulane University Health Services

    New Orleans, Louisiana

  • Silverton Skin Institute

    Grand Blanc, Michigan

  • Zoe Draelos, MD

    High Point, North Carolina

  • Haber Dermatology

    Euclid, Ohio

  • Oregon Dermatology and Research Center

    Portland, Oregon

  • Paddington Testing Company

    Philadelphia, Pennsylvania

  • Temple University School of Podiatric Medicine

    Philadelphia, Pennsylvania

  • Coastal Carolina Research Center

    Mt. Pleasant, South Carolina

  • J & S Studies

    College Station, Texas

  • Research Across America

    Dallas, Texas

  • Research Across America

    Plano, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.